Brief: Lexeo Therapeutics Granted FDA Fast Track Designation For LX2006
16/04/2024 13:13
April 16 (Reuters) - Lexeo Therapeutics Inc LXEO.O :
* LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR
LX2006, AN AAV-BASED GENE THERAPY CANDIDATE FOR THE TREATMENT OF
FRIEDREICH’S ATAXIA CARDIOMYOPATHY
Source text for Eikon: ID:nGNX8r4MS
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease